Nilotinib Viatris (Nilotinib)

Nilotinib binds to the ATP‑binding pocket of the BCR‑ABL tyrosine kinase, blocking its activity. This inhibition stops downstream signaling that drives uncontrolled cell growth, leading to reduced proliferation of leukemic cells.

The exact dose of nilotinib is determined by the prescribing physician based on clinical guidelines, disease phase, patient weight, and tolerability. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Nilotinib is not recommended during pregnancy or lactation because safety data are limited and potential risks to the fetus or infant exist. Women of child‑bearing potential should use effective contraception and discuss alternatives with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Both nilotinib and imatinib inhibit BCR‑ABL, but nilotinib is a second‑generation inhibitor with higher potency and activity against many imatinib‑resistant mutations. Clinical studies show faster and deeper molecular responses with nilotinib, though safety profiles differ and choice depends on individual patient factors.

Store the tablets at ambient temperature, preferably below 25 °C. Keep them in the original blister pack, protect from moisture and direct light, and keep out of reach of children.

Nilotinib is taken orally, usually as whole tablets with a low‑fat meal. Patients should swallow the tablets whole with water and follow the timing and dietary instructions provided by their prescriber.

Serious risks include cardiovascular events such as arterial occlusion, QT interval prolongation leading to arrhythmias, severe liver toxicity, pancreatitis, and rare hypersensitivity reactions. Patients should report chest pain, palpitations, jaundice, severe abdominal pain or any signs of an allergic reaction promptly.

Nilotinib should be avoided in patients with a known hypersensitivity to the drug, those with uncontrolled cardiovascular disease, significant QT prolongation, or severe hepatic impairment. It is also contraindicated in pregnant or breastfeeding women unless the benefits outweigh the risks.